Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact

Isin CA91911K1021
Ticker VRX
Currency $
Aware Investor Index (AII) 0.0000
Recommendation STRONG SELL
P/E 239.46
ROE 1.20 %
Capitalization 15,616,795,000 $
Dividend Yield 0.00 %
P/S 1.89
AII Position 776
P/E Position 766
ROE Position 779
Capitalization Position 415
Dividend Yield Position 629
Sales 8,263,500,000 $
10-Year Average Earnings 65,217,000 $
Shares Outstanding 341,500,000
Equity 5,434,500,000 $
Dividend per Share 0 $
Industry Pharmaceutical
Country Canada
VALEANT PHARMACEUTICALS INTERNATIONAL Investor Relations Web Site http://ir.valeant.com


2014 12 8,263,500,000.00 $
2013 12 5,769,605,000.00 $


2014 12 913,500,000.00 $
2013 12 -866,142,000.00 $
2012 12 -116,025,000.00 $
2011 12 159,559,000.00 $
2010 12 -208,193,000.00 $
2009 12 176,455,000.00 $
2008 12 199,904,000.00 $
2007 12 103,541,000.00 $
2006 12 228,939,000.00 $
2005 12 60,632,000.00 $


2014 12 5,434,500,000.00 $
2013 12 5,233,322,000.00 $
2012 12 3,717,398,000.00 $

Shares Outstanding:

2014 12 341,500,000
2013 12 320,996,000
2012 12 303,861,000



Jan 6, 2011
U.S. Stock Options With Biggest Changes in Implied Volatility
1500 CVE CENOVUS ENE CVE US 03/19/11 C22.5 17.3 55.9 10.30 -5.5 500 VRX VALEANT PHA VRX US 01/22/11 C32 17.1 38.9 3.30 407.7 1291 CSX CSX CORP CSX US 01/22/11...
Jan 3, 2011
U.S. Stock Options With Biggest Changes in Implied Volatility
1368 SSO PROSHARES U SSO US 01/22/11 C40 16.9 53.7 9.27 14.4 517 VRX VALEANT PHA VRX US 01/22/11 C26 16.8 47.4 3.05 -7.6 1000 CSCO CISCO SYSTE CSCO US 01/22/11...
Oct 2, 2008
North and South American Stock Rating Changes, New Coverage
-------------------------------------------------------------------------------- Valeant Pharmaceuticals Inte (VRX US) Matrix/Lighthouse Analyst Recommendation Action Target Team Coverage...
Feb 27, 2006
In India, Selling Generics Used To Be So Easy
Jersey, and bought an Ohio factory from California-based Valeant Pharmaceuticals International (VRX ). In December, Bombay's Glenmark Pharmaceuticals announced a deal with InvaGen Pharmaceuticals...
Dec 1, 2003
A New Way To Fight Hepatitis C
better at bypassing the blood cells and going straight to the liver. Valeant Pharmaceuticals (VRX), formerly ICN Pharma-ceuticals (ICN), developed both drugs. And it announced in early November...
Apr 21, 2011
ARC Resources, Celestica, Silver Wheaton: Canada Equity Preview
Steven Butler, an analyst at Canaccord Financial Inc. Valeant Pharmaceuticals International Inc. (VRX CN): Canada’s largest drugmaker said it is prepared to “modestly” raise its bid for Cephalon Inc...
Nov 10, 2011
Zweig Dimenna Partners Holdings in 3rd Quarter: 13F Alert
Freeport-McMoRan Copper FCX US -21,681,938 173,360 -336,295 Valeant Pharmaceuticals Inte VRX US -20,560,233 124,345 -360,180 Williams Cos Inc WMB US -17,574...
Sep 28, 2011
Allon, PetroAmerica, Rare Element, TMX: Canadian Equity Preview
offered to buy TMX for C$3.73 billion ($3.65 billion). Valeant Pharmaceuticals International Inc. (VRX CN): The drugmaker received approval for colesevelam hydrochloride, a treatment to help lower LDL...
Feb 15, 2011
ValueAct Holdings Largest Holdings in 4th Qtr: 13F Alert
(USD $) Position In Position Valeant Pharmaceuticals Inte VRX US 762,695,599 26,959,901 Sara Lee Corp SLE US 611,428...
Feb 14, 2011
Brahman Capital Corp Largest Holdings in 4th Quarter: 13F Alert
Technologies Holding ST US 70,728,842 2,349,015 2,349,015 Valeant Pharmaceuticals Inte VRX US 65,248,056 2,306,400 -254,700 Xerox Corp XRX US 57,273...


Simply Wall St - 8 Dec 2017
Should You Be Tempted To Buy Valeant Pharmaceuticals ...
Valeant Pharmaceuticals International Inc (NYSE:VRX) is trading with a trailing P/E of 4.5x, which is lower than the industry average of 23.3x. While this makes VRX appear like a great stock to buy, you might change your mind after I explain the assumptions behind the P/E ratio. In this article, I will break ...
Seeking Alpha
Investors watching Analysts Rating of Valeant Pharmaceuticals ...
Valeant Pharmaceuticals International, Inc. (VRX) deteriorated -0.30% to strike $16.73 in the Monday trading session. The stock's quarterly performance specifies a shift of -24.13% and its performance is stands at 49.37% for last twelve month while moved 19.59% for the past six months. 7.02 million shares ...
Valeant Pharmaceuticals International (VRX) Q4 2017 Results ...
Good morning. My name is Amy, and I will be your conference operator today. At this time, I would like to welcome everyone to the Valeant's Fourth Quarter and Full Year 2017 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a ...
PR Newswire (press release)
Should You Buy Valeant Pharmaceuticals International, Inc. (VRX ...
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) shares are down more than -19.49% this year and recently decreased -0.30% or -$0.05 to settle at $16.73. The Gap, Inc. (NYSE:GPS), on the other hand, is down -6.81% year to date as of 03/16/2018. It currently trades at $31.74 and has returned ...
Wall Street Morning - 8 hours ago
What Should Investors Know About The Future Of Valeant ...
The latest earnings release Valeant Pharmaceuticals International Inc's (NYSE:VRX) announced in December 2017 indicated that the business finally turned profitable after delivering negative earnings on average over the past couple of years. Today I want to provide a brief commentary on how market ...
Seeking Alpha - 28 Feb 2018
Earnings per share (EPS) in Focus – Valeant Pharmaceuticals ...
Valeant Pharmaceuticals International Inc (NYSE: VRX) is a stock with 349.76M shares outstanding. As the earnings per share (EPS) formula is stated as earnings available to common shareholders divided by number of common stock shares outstanding, therefore its diluted EPS is calculated to be 4.07 ...
Should Investors Listen To Analyst Recommendations?: Valeant ...
Valeant Pharmaceuticals International, Inc. (VRX) stock price recent trade pushed it move about -31.31% away from the 52-week high and closed 101.90% away from the 52-week low. VRX stock price traded with dropping change along with the volume 9.57 million shares in Thursday trading session.
4 Key Takeaways From Valeant Pharmaceuticals' 4th Quarter
Shares of Valeant Pharmaceuticals (VRX) closed at a price close to 30 percent below my $19 fair value assessment. On the surface, fourth-quarter revenue fell 10 percent while Bausch + Lomb sales fell. Though management forecasts revenue of over $11 billion solely on one product like VYZULTA, it still ...
PR Newswire (press release)
Valeant Pharma (NYSE:VRX) Hold Rating Has Just Been Reiterated ...
Investors sentiment decreased to 0.99 in 2017 Q3. Its down 0.09, from 1.08 in 2017Q2. It is negative, as 43 investors sold Valeant Pharmaceuticals International, Inc. shares while 68 reduced holdings. 27 funds opened positions while 83 raised stakes. 169.87 million shares or 1.18% less from 171.89 million ...
StockNewsGazette - 59 minutes ago
Earnings Preview: Valeant Pharmaceuticals
When Valeant Pharmaceuticals (VRX) reports quarterly earnings on Feb. 28 before the market opens, shareholders will look for more data points pointing to revenue stabilization and even growth in its core businesses. Markets are on the fence with the stock. After its last earnings report, investors bid the ...